Angiogenesis Inhibitors and Vascular Targeting

Angiogenesis inhibitors are agents that block the formation of new blood vessels that tumours need in order to grow beyond a small size and to spread. By interrupting the signals that drive vessel growth — most prominently the vascular endothelial growth factor (VEGF) pathway — these drugs aim to starve the tumour of its blood supply, a strategy distinct from killing cancer cells directly.

Definition

Angiogenesis inhibitors are agents that suppress the growth of new blood vessels into a tumour, typically by blocking the vascular endothelial growth factor pathway, thereby limiting the tumour's blood supply and its capacity to grow and metastasise.

Scope

This topic covers the concept of tumour angiogenesis, the VEGF signalling axis that drives it, the main therapeutic approaches (antibodies that neutralise VEGF, small-molecule inhibitors of VEGF receptor kinases, and decoy receptors), and the idea of vascular normalisation. It is reference-educational and contains no dosing or individualised treatment advice.

Core questions

• Why do tumours need new blood vessels to grow beyond a small size?
• What is the role of vascular endothelial growth factor in tumour angiogenesis?
• How do anti-VEGF antibodies, receptor kinase inhibitors, and decoy receptors differ?
• What is meant by vascular normalisation, and why might it matter?

Key concepts

• Tumour angiogenesis
• Angiogenic switch
• Vascular endothelial growth factor (VEGF)
• VEGF receptor (VEGFR) signalling
• Anti-VEGF monoclonal antibody
• VEGFR tyrosine kinase inhibitor
• Decoy receptor (VEGF trap)
• Vascular normalisation

Key theories

Tumour angiogenesis dependence

Judah Folkman proposed that tumours cannot grow beyond a few millimetres without recruiting their own blood supply, making angiogenesis a rate-limiting step in tumour growth and metastasis and therefore a therapeutic target; blocking the new vessels was hypothesised to restrain the tumour.

Mechanisms

Growing tumours outstrip the diffusion limit of oxygen and nutrients and must recruit new vessels to continue expanding — an event termed the angiogenic switch. Hypoxia and oncogenic signalling drive tumour cells to secrete pro-angiogenic factors, of which vascular endothelial growth factor (VEGF) is central; VEGF binds receptor tyrosine kinases on endothelial cells, stimulating their proliferation, migration, and the assembly of new capillaries. Anti-angiogenic therapy interrupts this pathway at several points: monoclonal antibodies neutralise circulating VEGF, small-molecule tyrosine kinase inhibitors block the intracellular kinase domain of VEGF receptors, and soluble decoy receptors sequester the ligand. Beyond simply reducing vessel number, blocking VEGF can transiently normalise the abnormal, leaky tumour vasculature, a proposed mechanism by which anti-angiogenic agents may improve delivery of co-administered cytotoxic drugs. Because these agents act on a physiological process shared with normal tissues, their effects are not entirely tumour-specific.

Clinical relevance

Anti-angiogenic therapy is a leading example of targeting the tumour's microenvironment and blood supply rather than the cancer cell itself, and it illustrates how a basic-science hypothesis about tumour biology translated into a therapeutic class. This entry explains the mechanism to support understanding of how the class is categorised and acts; it is reference-educational and not a basis for individual diagnostic or treatment decisions.

Evidence & guidelines

Clinical proof of principle came when bevacizumab, a monoclonal antibody against VEGF, added to chemotherapy improved outcomes in metastatic colorectal cancer in a randomised trial — the first demonstration that an anti-angiogenic agent could prolong survival. Subsequent VEGF-pathway agents, including receptor tyrosine kinase inhibitors and decoy receptors, were developed across several tumour types, and mechanistic reviews framed angiogenesis as an established therapeutic target.

History

Judah Folkman's 1971 proposal that tumour growth is angiogenesis-dependent reframed cancer biology and suggested that blocking new vessel formation could be therapeutic. The identification and cloning of vascular endothelial growth factor by Napoleone Ferrara and colleagues in the late 1980s provided a defined molecular target. This work led to bevacizumab, the first anti-VEGF antibody to show a survival benefit in 2004, and to a broader class of VEGF-pathway inhibitors and the concept of vascular normalisation.

Debates

Does anti-angiogenic therapy work mainly by starving tumours or by normalising their vasculature?

Reducing blood supply and transiently normalising abnormal tumour vessels are competing mechanistic explanations; vascular normalisation could paradoxically improve delivery of other drugs, complicating how anti-angiogenic agents are best combined and interpreted.

Key figures

• Judah Folkman
• Napoleone Ferrara
• Robert Kerbel
• Rakesh Jain

Seminal works

• folkman-1971
• leung-1989
• hurwitz-2004
• ferrara-2005

Frequently asked questions

How do angiogenesis inhibitors fight cancer?

They block the signals — chiefly the VEGF pathway — that tumours use to grow new blood vessels, aiming to limit the tumour's blood supply and its ability to grow and spread, rather than killing cancer cells directly.

What is vascular normalisation?

It is the idea that blocking VEGF can temporarily make a tumour's abnormal, leaky blood vessels more like normal vessels, which may improve the delivery of co-administered chemotherapy; it is one proposed mechanism for how anti-angiogenic drugs act.